0.2% brimonidine对开角型青光眼及高眼压症的临床疗效

目的 :评价 0 .2 %brimonidine滴眼对原发性开角型青光眼及高眼压症的降眼压效果及安全性。方法 :2 5例患者 4 1只眼纳入为期 6个月的前瞻性研究。在停用其他抗青光眼药物足够长的时间后测量基础值 ,予 0 .2 %bri monidine点眼每日两次 (8AM ,8PM) ,每月复查一次 ,测量低谷眼压 (用药 12h后眼压 )和高峰眼压 (用药 2h后眼压 )等 ,每 3个月复查视野一次。结果 :每次随访中 0 .2 %brimonidine均能显著降低患者低谷及高峰眼压 (P <0 .0 5 ) ;复查2 4h眼压波动每一时间眼压均较用药前显著降低 (P <0 .0 5 ) ;用药后 3月及 6月复查视野示药物对视功能无明显影响 (P >0 .0 5 )。观察期间未发现严重全身副作用。结论 :0 .2 %brimonidine对开角型青光眼及高眼压症具有稳定的降眼压效果 ,是一种具有良好耐受性 ,同时安全、有效的抗青光眼新药

Clinical efficacy of 0.2% brimonidine in patients with open-angle glaucoma or ocular hypertension

Objective To evaluate the efficacy and safety of 0.2% brimonidine administered in patients with glaucoma or ocular hypertension. Methods Twenty five patients (41 eyes) with primary open angle glaucoma or ocular hypertension were enrolled in this prospective study. Eye drops of 0.2% brimonidine were used twice daily for 6 months and the patients were examined every month after the treatment, including the trough intraocular pressure (IOP, IOP 12 h after 0.2% brimonidine was administrated) and the peak IOP (IOP 12 h after 0.2% brimonidine was administrated). The visual field was examined every three months. Results The use of 0.2% brimonidine significantly lowered the trough IOP and the peak IOP (P<0.05). Every point of the IOP diurnal curve significantly decreased compared with the baseline (P<0.05).The visual field had no significant change 3 months or 6 months after the treatment with 0.2% brimonidine. No serious systemic side effect was observed.Conclusion Brimonidine is safe and effective in lowering IOP in glaucoma or ocular hypertension and is well tolerated.